Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Collplant Holdings Ltd (NASDAQ: CLGN).

Full DD Report for CLGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLGN)

CollPlant to Ring Nasdaq Opening Bell on November 8, 2018
NESS ZIONA, Israel , November 7, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that management will be ringing ...
Source: PR Newswire
Date: November, 07 2018 10:00
CollPlant Shares Will Be Traded From Tuesday Oct 30 Exclusively on Nasdaq
NESS ZIONA, Israel , Oct. 28, 2018 /PRNewswire/ --  CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that as from Tuesday, Octob...
Source: PR Newswire
Date: October, 28 2018 08:00
CollPlant Holdings to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
NESS ZIONA, Israel , August 28, 2018 /PRNewswire/ -- CollPlant ( NASDAQ: CLGN ) ( TASE: CLGN ) a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it will be featu...
Source: PR Newswire
Date: August, 28 2018 07:00
Dual-Listed CollPlant to Voluntarily Delist From Tel Aviv Stock Exchange
NESS ZIONA, Israel , Aug. 8, 2018 /PRNewswire/ --  CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that the Company is volunt...
Source: PR Newswire
Date: August, 08 2018 09:00
CollPlant Appoints Dr. Wolfgang Ruttenstorfer to Its Board of Directors
NESS ZIONA, Israel , July 5, 2018 /PRNewswire/ --  CollPlant (NASDAQ: CLGN) (TASE: CLGN),   a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced the appointmen...
Source: PR Newswire
Date: July, 05 2018 05:55
CollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs
NESS ZIONA, Israel , June 26, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it has received grant ...
Source: PR Newswire
Date: June, 26 2018 05:55
CollPlant Appoints Professor Shay Soker from Wake Forest Institute for Regenerative Medicine to its Scientific Advisory Board
NESS ZIONA, Israel , June 19, 2018 /PRNewswire/ -- CollPlant (NASDAQ:CLGN) (TASE:CLGN),   a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced the appointment of Shay ...
Source: PR Newswire
Date: June, 19 2018 07:55
CollPlant reports Q1 results
CollPlant (NASDAQ: CLGN ): Q1 EPS of $0.01 More news on: CollPlant, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 24 2018 06:03
CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update
NESS ZIONA, Israel , May 24, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced financial results for th...
Source: PR Newswire
Date: May, 24 2018 05:50
CollPlant Files U.S. Patent Application for Next Generation Dermal Filler
NESS ZIONA, Israel , May 8, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has filed a provisional...
Source: PR Newswire
Date: May, 08 2018 06:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-084.92655.185.184.86082,223
2018-05-17N/A5.70N/AN/A60

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-129387310.6529Cover
2018-12-1110031831.4465Cover
2018-12-102,9734,17371.2437Short
2018-12-0770092575.6757Short
2018-12-061,4002,65052.8302Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLGN.


About Collplant Holdings Ltd (NASDAQ: CLGN)

Logo for Collplant Holdings Ltd (NASDAQ: CLGN)

CollPlant is a regenerative medicine company leveraging its proprietary, plant based recombinant human collagen rhCollagen technology for the development and commercialization of tissue repair products, initially for D Bio printing of tissue and organs, for orthobiologics and advanced wound care markets. The Company s cutting edge technology is designed to generate and process proprietary rhCollagen, among other patent protected recombinant proteins. Given that CollPlant s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix R STR Soft Tissue Repair Matrix , for the treatment of tendinopathy and Vergenix R FG Flowable Gel wound filler, for treatment of acute and chronic wounds. CollPlant s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.

 

Contact Information

 

 

Current Management

  • Yehiel Tal / CEO
  • Ilana Belzer / COO
  • Eran Rotem / CFO
  • Philippe Bensimon / VP, Regulatory Affairs
  • Nadav Orr / VP, R amp D
  • Shomrat Shurtz / VP, Sales amp Mktg.
  • Oded Shoseyov / CSO
  • Talya Zavchon / Controller
  • David Tsur / Chairman
  • Scott R. Burell /
  • Adi Goldin / Nominating Committee Member
  • Gili Hart / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Abraham Havron / Independent Director, Audit Committee Member, Compensation Committee Member
  • Elan Penn /

Current Share Structure

  • Market Cap: $19,017,057 - 05/15/2018
  • Issue and Outstanding: 166,816,287 - 12/31/2017

 


Recent Filings from (NASDAQ: CLGN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 03 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 12 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 09 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 21 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 20 2018

 

 


Daily Technical Chart for (NASDAQ: CLGN)

Daily Technical Chart for (NASDAQ: CLGN)


Stay tuned for daily updates and more on (NASDAQ: CLGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLGN and does not buy, sell, or trade any shares of CLGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/